At Drug Pricing Hearing, Innovator Companies Mainly Escape Congressional Wrath
This article was originally published in The Pink Sheet Daily
Executive Summary
Members of House Oversight Committee accuse Turing and Valeant of 'trashing' mainstream innovator companies with their drug pricing practices.